Laouirem Samira, Le Faouder Julie, Alexandrov Theodore, Mestivier Denis, Léger Thibaut, Baudin Xavier, Mebarki Mouniya, Paradis Valérie, Camadro Jean-Michel, Bedossa Pierre
INSERM U773, Université Paris-Diderot, Sorbonne Paris Cité, Paris, France.
J Pathol. 2014 Dec;234(4):452-63. doi: 10.1002/path.4398. Epub 2014 Sep 12.
Cirrhosis is a lesion at risk of hepatocellular carcinoma (HCC). Identifying mechanisms associated with the transition from cirrhosis to HCC and characterizing biomarkers of cirrhosis at high risk of developing into cancer are crucial for improving early diagnosis and prognosis of HCC. We used MALDI imaging to compare mass spectra obtained from tissue sections of cirrhosis without HCC, cirrhosis with HCC, and HCC, and a top-down proteomics approach to characterize differential biomarkers. We identified a truncated form of monomeric ubiquitin lacking the two C-terminal glycine residues, Ubi(1-74), the level of which increased progressively, from cirrhosis without HCC to cirrhosis with HCC to HCC. We showed that kallikrein-related peptidase 6 (KLK6) catalysed the production of Ubi(1-74) from monomeric ubiquitin. Furthermore, we demonstrated that KLK6 was induced de novo in cirrhosis and increased in HCC in parallel with accumulation of Ubi(1-74). We investigated in vitro the possible consequences of Ubi(1-74) accumulation and demonstrated that Ubi(1-74) interferes with the normal ubiquitination machinery in what is likely to be a kinetic process. Our data suggest that de novo KLK6 expression during early liver carcinogenesis may induce production of Ubi(1-74) by post-translational modification of ubiquitin. Given the deleterious effect of Ubi(1-74) on protein ubiquitination and the major role of ubiquitin machinery in maintenance of cell homeostasis, Ubi(1-74) might severely impact a number of critical cellular functions during transition from cirrhosis to cancer. Ubi(1-74) and KLK6 may serve as markers of cancer risk in patients with cirrhosis.
肝硬化是肝细胞癌(HCC)的一种风险病变。识别与从肝硬化转变为HCC相关的机制,并确定具有高癌变风险的肝硬化生物标志物,对于改善HCC的早期诊断和预后至关重要。我们使用基质辅助激光解吸电离成像技术(MALDI成像)比较了从无HCC的肝硬化、伴有HCC的肝硬化以及HCC的组织切片中获得的质谱,并采用自上而下的蛋白质组学方法来表征差异生物标志物。我们鉴定出一种缺少两个C末端甘氨酸残基的截短形式的单体泛素,即Ubi(1 - 74),其水平从无HCC的肝硬化到伴有HCC的肝硬化再到HCC逐渐升高。我们发现激肽释放酶相关肽酶6(KLK6)催化单体泛素生成Ubi(1 - 74)。此外,我们证明KLK6在肝硬化中从头诱导产生,并在HCC中随着Ubi(1 - 74)的积累而增加。我们在体外研究了Ubi(1 - 74)积累可能产生的后果,并证明Ubi(1 - 74)可能在一个动力学过程中干扰正常的泛素化机制。我们的数据表明,在肝癌发生早期KLK6的从头表达可能通过泛素的翻译后修饰诱导Ubi(1 - 74)的产生。鉴于Ubi(1 - 74)对蛋白质泛素化的有害作用以及泛素机制在维持细胞内稳态中的主要作用,Ubi(1 - 74)可能在从肝硬化到癌症的转变过程中严重影响许多关键的细胞功能。Ubi(1 - 74)和KLK6可能作为肝硬化患者癌症风险的标志物。